Vaughn M Kailian's Net Worth
$1.28 Million
Who is Vaughn M Kailian?
Vaughn M Kailian has an estimated net worth of $1.28 Million. This is based on reported shares across multiple companies, which include PEPLIN INC, TriVascular Technologies, Inc., Radius Health, Inc., Verastem, Inc., Syndax Pharmaceuticals Inc, Pacira Pharmaceuticals, Inc., ARATANA THERAPEUTICS, INC., Conatus Pharmaceuticals Inc, Epizyme, Inc., Cerecor Inc., CEPHALON INC, CHIASMA, INC, VIACELL INC, MEMORY PHARMACEUTICALS CORP, and MILLENNIUM PHARMACEUTICALS INC.
SEC CIK
Vaughn M Kailian's CIK is 0001180429
Past Insider Trading and Trends
2004 was Vaughn M Kailian's most active year for acquiring shares with 3 total transactions. Vaughn M Kailian's most active month to acquire stocks was the month of April. 2011 was Vaughn M Kailian's most active year for disposing of shares, totalling 7 transactions. Vaughn M Kailian's most active month to dispose stocks was the month of September. 2003 saw Vaughn M Kailian paying a total of $476,273.52 for 152,988 shares, this is the most they've acquired in one year. In 2004 Vaughn M Kailian cashed out on 105,130 shares for a total of $1,757,500.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
PEPLIN INC No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -3.42M |
—
|
—
|
0
|
Nov 11
| |||
Form 4
| +0.07% | 2.25K |
$8.11 | $18,233.80 | 3.42M |
Feb 11 - Feb 12
| |||
Form 4
| +0.03% | 1K |
$8.00 | $7,992.00 | 3.42M |
Feb 9
| |||
Form 4
| +0.08% | 2.65K |
$7.80 | $20,654.40 | 3.42M |
Feb 5
| |||
Form 4
| +0.23% | 7.71K |
$8.04 | $61,948.00 | 3.41M |
Jan 23 - Jan 27
| |||
Form 4
| +0.10% | 3.52K |
$8.07 | $28,369.80 | 3.41M |
Jan 21 - Jan 22
| |||
Form 4
| +0.29% | 9.88K |
$8.14 | $80,402.20 | 3.4M |
Jan 15 - Jan 20
| |||
Form 4
| +0.20% | 6.91K |
$7.03 | $48,584.33 | 3.39M |
Jan 13
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
TriVascular Technologies, Inc. No price found
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 1.78M |
—
|
—
| 1.78M |
Apr 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Syndax Pharmaceuticals Inc (SNDX) Snapshot price: $19.1
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 2.17M |
—
|
—
| 2.17M |
Mar 8
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Pacira Pharmaceuticals, Inc. (PCRX) Snapshot price: $13.89
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -15.20% | -500.00K |
$27.86 | -$13,930,000.00 | 2.79M |
Mar 11
| |||
Form 4
| +16.31% | 461.54K |
$6.50 | $2,999,997.00 | 3.29M |
Nov 21
| |||
Form 4/A
| +2,942.53% | 2.74M |
$7.00 |
—
| 2.83M |
Feb 8
| |||
Form 4
| +2,942.53% | 2.74M |
$7.00 |
—
| 2.83M |
Feb 8
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
ARATANA THERAPEUTICS, INC. No price found
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -17.90% | -600.00K |
$20.02 | -$12,012,000.00 | 2.75M |
Mar 10
| |||
Form 4
| -19.93% | -872.70K |
—
|
—
| 3.51M |
Mar 3
| |||
Form 4
| +944.84% | 3.93M |
$6.00 |
—
| 4.35M |
Jul 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |